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Abstract 
Thrombus formation at the surface of blood contacting devices can be prevented by local release of heparin. Preferably, 
the release rate should be constant for prolonged periods of time. The minimum heparin release rate to achieve 
thromboresistance will be different for various applications and should therefore be adjustable. In this study a new type of 
heparin release system is presented which may be applied as a coating for blood contacting devices. The system is based on 
the covalent immobilization of heparin onto porous structures via hydrolysable bonds. This approach was evaluated by the 
immobilization of heparin onto a porous cellulosic substrate via ester bonds. Cuprophan was used as a model substrate and 
N,N'-carbonyldiimidazole as a coupling agent. Heparinized Cuprophan incubated in phosphate buffered saline showed a 
release of heparin due to the hydrolysis of the ester bonds between heparin and Cuprophan. The release rate could be easily 
adjusted by varying the amount of coupling agent used during immobilization. Cuprophan with a rather stable heparin 
coating (release rate: 6.1 mU/cm2'h) and Cuprophan which shows a substantial release of heparin (release rate up to 23.0 
mU/cm2.h) could be prepared. Except when the release was relatively high, release rates were constant for at least 1 week. 
Storage of the release system at ambient conditions up to 6 months or sterilization by means of steam, ethylene oxide 
exposure, or gamma irradiation did not affect the release properties. It was concluded that this concept for a heparin release 
system is highly promising to prepare thromboresistant surfaces for various blood contacting devices. 
Keywords: Antithrombogenicity; Controlled release; Heparin; Hydrolysis of covalent bonds; Porous structures 
1. Introduction 
The application of blood contacting devices can be 
complicated by the formation of thrombi at their 
surface. Heparin is a very powerful anticoagulant. 
Therefore, an often applied strategy to prevent 
thrombus formation is to covalently immobil ize 
heparin at the surface [1,2]. Immobil ized heparin 
may interact with factors of the coagulation cascade 
Corresponding author. 
thereby preventing thrombus formation. A disadvan- 
tage is that due to immobilization, the mobility of 
heparin is limited, even when spacers are used. As a 
result the activity of immobil ized heparin can be 
strongly reduced as compared to unbound heparin 
[3-5]. Another strategy to prevent hrombus forma- 
tion is to create a microenvironment of heparin at the 
surface of blood contacting devices [6-11]. Despite 
much research, the minimum heparin concentration 
which is required to achieve thromboresistance in 
such a microenvironment is still unknown. In litera- 
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ture, concentrations of 0.2-7.0 p~g/ml have been 
mentioned [12,13]. A microenvironment of heparin 
can be achieved by the immobilization of heparin at 
the surface and a subsequent release of heparin from 
the surface into blood. Since heparin is consumed in 
blood and transported along with the blood flow, a 
continuous release of heparin from the device is 
necessary to maintain the heparin concentration near 
the surface at the same level. Also with regard to the 
minimum release rate necessary to guarantee throm- 
boresistance, there is some debate. Obviously, the 
minimum release rate will depend on the blood flow 
rate at the site of application and the geometry of the 
blood contacting device. Besides the consumption of 
heparin, these factors determine the depletion of 
heparin from the microenvironment [12]. But also 
for one particular application there is some confu- 
sion. Tanzawa et al. [11] stated that a catheter 
inserted into the inferior vena cava in dogs should 
release 4×10 .2 txg/cm2.min to ensure throm- 
boresistance. In other reports, however, a ten times 
lower minimum release rate has been claimed for the 
same application [10,14]. Others proposed that the 
release rate can be much lower because heparin 
remaining immobilized at the surface will also 
display antithrombogenic a tivity [12,15-17]. 
Many types of heparin release systems have been 
developed. In most of these systems, heparin is 
immobilized by dispersing heparin within the bioma- 
terial [7,18,19] or by ionic binding of heparin onto 
the biomaterial [6,8-11,14,20-22]. In most cases, 
after incubation in aqueous alt solutions, plasma, or 
blood, the heparin release rate is initially very high 
but decreases very rapidly in time [6,7,9,20,21,23- 
25]. Usually no release of heparin can be detected 
anymore already after 1-24 h while for many 
applications a release during a period of days to 
weeks is required. Only incidentally a prolonged 
release of heparin has been claimed [8,10,11,14,22]. 
From the discussion above, it is clear that there is 
a need for a heparin release system with which the 
release rate remains constant for a prolonged period 
of time and of which the release rate can be easily 
adjusted. 
In this study, a new concept is presented for a 
heparin release system which meets these require- 
ments. This concept is based on a combination of 
two different approaches. Firstly, heparin is cova- 
lently immobilized onto a substrate via hydrolysable 
bonds. By changing the heparinization conditions, 
the number of covalent bonds between heparin and 
the substrate can be adjusted and therefore also the 
release rate. Secondly, the substrate has a porous 
structure. By using a porous structure, a very high 
surface area is available for heparin immobilization. 
A very high amount of immobilized heparin guaran- 
tees the continuous upply of heparin for prolonged 
periods of time to be released. Furthermore, because 
of the very high amounts of immobilized heparin, a 
constant release rate for prolonged periods of time 
may be expected. A release system according to this 
concept applied as coating for blood contacting 
devices may assure thromboresistance for long-term 
applications. In this study, a porous cellulosic mem- 
brane (Cuprophan) is used as a model substrate and 
N,N'-carbonyldiimidazole (CDI) is used as a cou- 
pling agent to immobilize heparin via hydrolysable 
bonds. 
2. Materials and methods 
2.1. Materials 
Cuprophan 150 M was a gift from AKZO (Wup- 
pertal, Germany). Formamide (synthesis grade, 
Merck, Darmstadt, Germany) was purified and dehy- 
drated according to a method as described by 
Verhoek et al. [26] and stored beneath a blanket of 
dry nitrogen. Heparin (sodium salt) from porcine 
intestinal mucosa (activity: 177 U/mg) was pur- 
chased from Diosynth (Oss, The Netherlands). 
Heparin also from porcine intestinal mucosa of 
which 55-60% of the sodium ions was substituted 
by benzyltrimethylammonium ions (heparin-triton B)
was purchased from HBG (Enschede, The Nether- 
lands). Chromogenic substrate $2222 was purchased 
from Chromogenix (M61ndal, Sweden). Polyethylene 
glycol (6000 g/mol, PEG); human antithrombin III 
(AT III, Sigma, St Louis, USA) was purified using a 
heparin-Sepharose column [3,27] (Sigma). Bovine 
albumin (Alb) and human activated factor X (factor 
Xa) were purchased from Sigma. Partial thrombop- 
lastin time (PTT) reagent was obtained from Boeh- 
ringer (Mannhein, Germany). CPDA-1 plasma (plas- 
ma supplemented with citrate, phosphate, dextrose, 
and adenine) was purchased from Rode Kruis Bloed- 
bank Twente-Achterhoek (Enschede, The Nether- 
W.L.J. Hinrichs et al. / Journal of Controlled Release 45 (1997) 163-176 165 
lands). Phosphate buffered saline (PBS, pH 7.4) was 
purchased from NPBI (Emmercompascuum, The 
Netherlands). Acetone, benzoic acid, benzyl alcohol, 
CDI, cyclohexanol, D20, glacial acetic acid, 1 N 
HC1, NaC1, 1 N NaOH, NaN 3, 4-phenyl-l-butanol, 
P205, toluidine blue O zinc chloride double salt, 
tris(hydroxymethyl)-ammonium methane (Tris) (all 
analytical grade) were purchased from Merck. All 
chemicals were used without further purification 
except when mentioned. 
2.2. Heparinization of Cuprophan 
37°C and stored on ice. To 50 p~l heparin solution in 
PBS, 50 txl plasma and 50 txl PTT reagent was 
added and mixed for 3 rain at 37°C. Thereafter, 50 
txl of an aqueous 20 mM CaC12 solution was added. 
The suspension was mixed again and the coagulation 
time was determined at 37°C using a coagulatometer 
(LC-6, Lode, Groningen, The Netherlands). A cali- 
bration curve was obtained by measuring the coagu- 
lation time of solutions of heparin in PBS of known 
activities (0-0.7 U/ml). The calibration curve was 
used to calculate the anticoagulant activity of the 
heparin solutions. 
Cuprophan was heparinized by means of a pro- 
cedure as described by Engbers et al. [28]. Heparin- 
triton B was dissolved in dry formamide beneath a 
blanket of dry nitrogen. CDI was added to the 
solution under vigorous stirring. Thereafter the pres- 
sure was reduced to about 10 -2 mBar. After 60 rain, 
the pressure was elevated to 1 atm with dry nitrogen 
after which the reaction mixture was transferred to 
Cuprophan membranes which had been thoroughly 
rinsed with formamide to remove glycerol and water. 
The immobilization reaction was also carried out 
beneath a blanket of dry nitrogen. After immobiliza- 
tion, the reaction was quenched by replacing the 
reaction mixture by demineralized water. Sub- 
sequently the membranes were thoroughly rinsed 
with demineralized water then incubated in an 
aqueous 4 M NaC1 solution. Thereafter, the mem- 
branes were again thoroughly rinsed with demineral- 
ized water, soaked in a 10 wt% solution of glycerol 
in demineralized water and then dried by air expo- 
sure. 
Immobilization was performed at weight ratios 
heparin/CDI of 5, 10, and 30 yielding membranes 
with 60-85 p~g immobilized heparin per cm 2 mem- 
brane surface area (defined as the outer surface of the 
membrane). The membranes were either not steril- 
ized or sterilized by steam, ethylene oxide (EtO) 
exposure, or gamma irradiation using standard pro- 
cedures [29]. 
2.3. Activated partial thromboplastin time (APTT) 
assay 
The anticoagulant activity of solutions of heparin 
in PBS was determined by means of an APTT assay. 
Fresh frozen human CPDA-1 plasma was thawed at 
2.4. Factor Xa inactivation assay 
The anticoagulant activity of solutions of heparin 
in PBS was also determined by means of a factor Xa 
inactivation assay. Therefore, solutions of substrate 
$2222 (2.0 mg/ml)/AT III (70 mU/ml) and solutions 
of factor Xa (0.4 U/ml) were prepared using a buffer 
solution consisting of an aqueous solution of 50 
mmol/1 Tris, 1.0 g/1 PEG, 1.0 g/l Alb, and 150 
mmol NaC1 which was adjusted to pH 8.4. To 150 txl 
of substrate $2222/AT III solution, 40 Ixl of the 
heparin solution was added. Subsequently, 50 txl of 
the factor Xa solution was added. The resulting 
mixture was shaken for 10 min at room temperature. 
Thereafter, the reaction was quenched by adding 70 
txl of 40 vol% acetic acid. Subsequently, 200 txl of 
the solution was taken from which the extinction was 
measured at 405 nm. A calibration curve was 
obtained using solutions of heparin in PBS of known 
activities (0-20 mU/ml). The calibration curve was 
used to calculate the activity of heparin in the 
solutions. 
2.5. Toluidine blue solution assay 
A toluidine blue assay was developed to study the 
effects of various treatments of heparin (see below) 
on the capacity of heparin to complex with toluidine 
blue or to determine the heparin concentration i  
solution. To 2 ml of a heparin solution in aqueous 
0.01 N HC1/0.2 wt% NaC1 or PBS, 2 ml of a freshly 
prepared solution of 0.04 wt% toluidine blue in 
aqueous 0.01 N HC1/0.2 wt% NaC1, was added. The 
mixture was gently shaken for 4 h during which the 
formed heparin/toluidine blue complex precipitated. 
Subsequently, the mixture was centrifugated at 
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1000×g for 10 rain. The amount of toluidine blue in 
the heparin/toluidine blue complex (i.e. the amount 
of toluidine blue in the precipitate) was determined 
as follows. The precipitate was rinsed with aqueous 
0.01 N HC1/0.2 wt% NaC1 and then dissolved in 5 
ml of a 4:1 (v/v) mixture of ethanol and aqueous 0.1 
N NaOH. The extinction of the resultant solution 
was measured at 530 nm. To obtain a calibration 
curve, the same procedure was carried out with 
solutions of untreated heparin of known concen- 
trations. The calibration curve was used to relate the 
capacity of treated heparin to complex with toluidine 
blue with untreated heparin or to determine the 
concentration of heparin in solution. 
brane was rinsed twice with demineralized water and 
then incubated into 5 ml of a 4/1 (v/v) mixture of 
ethanol and aqueous 0.1 N NaOH. In this medium 
the heparin/toluidine blue complex is broken and 
toluidine blue is released into the fluid phase. After 
complete decolourization of the membrane, the ex- 
tinction of the fluid phase was measured at 530 nm. 
The extinction was related to the amount of immobil- 
ized heparin using the calibration curve as described 
under 'toluidine blue solution assay'. The results of 
experiments using radiolabeled heparin confirmed 
that the heparin/toluidine blue ratio in the complex 
was the same for immobilized heparin and heparin in 
solution (data not shown). 
2.6. Toluidine blue membrane assay 2. 7. Activation of heparin with CDI 
The amount of immobilized heparin was deter- 
mined by a procedure as described by Smith et al. 
[30] and modified for our purposes. The membranes 
were cut in discs with a diameter of 7 mm. The 
immobilized heparin was stained by incubating the 
membrane in 5 ml of a freshly prepared solution of 
0.04 wt% toluidine blue in aqueous 0.01 N HC1/0.2 
wt% NaC1. After 4 h of gently shaking, the mere- 
Theoretically, CDI can activate carboxylic acid as 
well as hydroxyl groups [31] of heparin. The re- 
action of carboxylic acid groups with CDI results in 
the evolution of CO 2 whereas during the reaction of 
hydroxyl groups with CDI no CO 2 is formed (see 
Fig. la). The activation of heparin was therefore 
studied by measuring the evolution of CO 2 using an 
experimental set-up as shown in Fig. 2. To a solution 
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Fig. 1. (a) Activation reactions of carboxylic acid and hydroxyl groups with CDI. (b) Coupling reactions of CDI-activated carboxylic acid 
groups and CDI-activated hydroxyl groups with hydroxyl groups. 
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Fig. 2. Schematic drawing of the experimental set-up for the 
measurement of CO 2 release. 
of 666 mg heparin-triton B in 5 ml formamide, 1 
mmol CDI was added. After 1 h the amount of CO 2 
released from the reaction mixture was measured. 
Subsequently, a large excess of glacial acetic acid 
was added to allow any remaining CDI to react. The 
amount of CO 2 released from the reaction mixture 
after addition of glacial acetic acid was measured 
again. A calibration curve was obtained by measur- 
ing the amount of CO 2 released after addition of an 
excess of glacial acetic acid to solutions of various 
amounts of CDI in formamide. The calibration curve 
was used to relate the amount of released CO 2 to the 
amount of activated carboxylic acid groups of 
heparin and the amount of unreacted CDI after 1 h of 
activation. These values were used to calculate the 
amount of reacted hydroxyl groups of heparin. 
2.8. Immobilization of model compounds onto 
Cuprophan 
Benzoic acid and benzyl alcohol were used as 
model compounds for carboxylic acid and hydroxyl 
groups of heparin, respectively. The reactions of 
CDI-activated carboxylic acid and CDI-activated 
hydroxyl groups with the hydroxyl groups of Cup- 
rophan yield ester and carbonate bonds, respectively 
[31] (see Fig. lb). To immobilize the model com- 
pounds onto Cuprophan, the same procedure was 
applied as used for the immobilization of heparin 
onto Cuprophan. The immobilization times and the 
concentrations of the model compounds were varied. 
The amounts of immobilized benzoic acid or benzyl 
alcohol were determined as follows. The membranes 
were incubated in 0.1 N NaOH for 24 h at ambient 
temperature. FTIR-spectroscopy revealed that after 
incubation all covalent bonds between the model 
compounds and Cuprophan were broken (data not 
shown). The extinction of the NaOH/benzoic acid 
and NaOH/benzyl alcohol solutions was determined 
at 266 nm and 256 nm, respectively. Calibration 
curves were used to calculate the concentrations of
the model compounds. 
2.9. Coupling of heparin to model compounds 
Cyclohexanol and 4-phenyl-l-butanol were used 
as model compounds for Cuprophan. Heparin was 
covalently linked to the model compounds by means 
of the same procedure as used for the immobilization 
of heparin onto Cuprophan except hat after activa- 
tion of heparin with CDI, the reaction mixture was 
added to solutions of the model compounds in 
formamide instead of to Cuprophan. After coupling, 
the reaction mixtures were precipitated in and thor- 
oughly washed with acetone. Subsequently the pre- 
cipitates were dried over P205 in vacuo and then 
dissolved in D20. The resulting solutions were 
analysed with proton decoupled 13C-NMR spectros- 
copy. 
2.10. Release of heparin from heparinized 
Cuprophan in PBS 
Non-sterilized and sterilized heparinized Cup- 
rophan was incubated in tubes containing PBS. PBS 
was supplemented with NaN 3 (final concentration: 
0.02 wt%) to prevent bacterial growth. The tubes 
were placed in a water bath of 37°C and gently 
shaken. At different ime intervals, samples of PBS 
were taken and/or the membranes were rinsed with 
water, soaked into a 10 wt% solution of glycerol in 
water, and then dried by air exposure. The amount of 
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heparin released into PBS was determined by means 
of the APTT assay and in some cases also by means 
of the toluidine blue solution assay and the factor Xa 
inactivation assay. The amount of heparin remaining 
immobilized onto Cuprophan was determined by 
means of the toluidine blue membrane assay. 
2.11. Effect of storage 
in water are at 257, 262, and 268 nm, detection level 
was less than 1% of the original triton B con- 
centration, data not shown). 
The treated heparin samples were evaluated for 
their capacities to complex with toluidine blue 
(toluidine blue solution assay) and their anticoag- 
ulant activity (APTT assay). 
Non-sterilized Cuprophan heparinized at a weight 
ratio of heparin/CDI of 30 was exposed to air at 
ambient emperature for various time intervals up to 
6 months. Thereafter, the membranes were incubated 
in PBS at 37°C for 1 week. Before and after 
incubation the amount of immobilized heparin was 
determined by means of the toluidine blue membrane 
assay. 
2.12. Effects of various treatments of heparin on 
the complexation of heparin with toluidine blue 
and the anticoagulant activity of heparin 
The sodium salt of heparin was dissolved in PBS/ 
NaN 3 and kept at 37°C for 1 week. Subsequently, the 
solution was dialysed against demineralized water at 
4°C for 2 days, during which the dialysate was 
refreshed twice a day, and then lyophilized. In other 
control experiments heparin-triton B was dissolved 
in formamide and allowed to react with various 
amounts of CDI for 2 days. Subsequently, heparin 
was precipitated by pouring the reaction solution into 
a large excess of acetone. The precipitate was 
thoroughly washed with acetone and then dried by 
air exposure. Subsequently, heparin was dissolved in 
aqueous 4 M NaC1 to hydrolyse CDI-activated 
groups of heparin and to convert he triton B salt of 
heparin into its sodium salt (triton B/Na + = 1/100 
(mol/mol)). After three days, the solution was 
dialyzed against water at 4°C. After 1 day, an 
additional amount of NaC1 was added (triton B/Na + 
1:5, mol/mol). Dialysis was continued for 5 day 
during which the dialysate was refreshed twice a 
day. Thereafter the solution was lyophilized. In a 
third series of experiments, heparin-triton B was 
dissolved in aqueous 4 M NaC1 and treated likewise. 
Photospectrometry confirmed that during the pro- 
cedure heparin-triton B was completely converted 
into its sodium salt (extinctions of triton B dissolved 
3. Results 
3.1. Activation of heparin with CDI 
The activation of heparin with CDI was studied by 
measuring the evolution of CO z. After 1 h of 
activation, the reaction was quenched by the addition 
of an excess of glacial acetic acid. It was found that 
after quenching no CO 2 released. Therefore it is 
concluded that after 1 h of activation, all CDI had 
been reacted. From the amount of CO 2 released 
during activation, it was calculated that 69.7-+9.3 
mol% of CDI had activated carboxylic acid groups 
(n=3). It can be assumed that CDI only reacts with 
carboxylic acid and hydroxyl groups of heparin [31]. 
Therefore, the remaining amount of CDI, 30.3+9.3 
tool% had activated hydroxyl groups. 
3.2. Immobilization of model compounds onto 
Cuprophan 
Benzoic acid and benzyl alcohol were used as 
model compounds to compare the reactivity of CDI- 
activated carboxylic acid and CDI-activated hydroxyl 
groups towards the hydroxyl groups of Cuprophan. 
As shown in Fig. 3, CDI-activated carboxylic acid 
groups reacted much more rapidly with the hydroxyl 
groups of Cuprophan than CDI-activated hydroxyl 
groups (note the different ime scales in Fig. 3a and 
b). The initial reaction rate shows a linear relation- 
ship with the concentration of the model compounds 
(see Fig. 4). Therefore, the immobilization of the 
model compounds onto Cuprophan was for both 
cases a first order process for the model compounds. 
Also from these graphs it is clear that the reaction 
rate for the immobilization of CDI-activated benzoic 
acid (reaction constant defined as the slope of the 
line in Fig. 4:0.18-10 -3 cm/h) was much higher 
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alcohol. 
than that of CDI-activated benzyl alcohol (reaction 
constant: 0.012.10 -3 cm/h). 
3.3. Coupling of heparin to model compounds 
The immobilization mechanism of heparin onto 
Cuprophan was also studied using cyclohexanol and 
4-phenyl-l-butanol as model compounds for sec- 
ondary and primary hydroxyl groups of Cuprophan 
respectively. The products of the reactions between 
CDI-activated heparin and the model compounds 
were analyzed by means of t3C-NMR spectroscopy. 
~3C-NMR spectroscopy is a suitable technique to 
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Fig. 4. Initial rate of immobilization f CDI-activated model 
compound onto Cuprophan asa function of the concentration f 
the model compounds. Benzoic acid *, benzyl alcohol A. 
investigate whether ester or carbonate bonds were 
formed since these bonds yield distinct peaks at 167 
ppm and 155 ppm, respectively. In the 13C-NMR 
spectra of both reaction products, strong signals at 
167 ppm were observed while no signals at 155 ppm 
could be detected. Apparently, the reactions of CDI- 
activated heparin with secondary as well as primary 
hydroxyl groups were dominated by the formation of 
ester bonds while carbonate bonds were not or hardly 
formed. 
3.4. Release of heparin from heparinized 
Cuprophan in PBS 
The release of heparin from heparinized Cup- 
rophan in PBS at 37°C was investigated. The release 
of heparin during 1 week of incubation as deter- 
mined by means of the APTT-assay as a function of 
time was linear for Cuprophan heparinized at weight 
ratios heparin/CDI of 5 and 10 while for Cuprophan 
heparinized at a weight ratio heparin/CDI of 30 this 
linearity was lost after three days of incubation (see 
Fig. 5). The amount of released heparin after 1 week 
of incubation was also determined by means of the 
factor Xa inactivation assay and by both toluidine 
blue assays. The data were analysed by means of 
ANOVA analysis of variance and considered as 
significantly different when P<0.05. The results of 
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Fig. 5. Release of heparin from Cuprophan heparinized at various 
heparin/CD1 ratios (weight ratio heparin/CDI of 5 II, 10., 30 A) 
after incubation in PBS at 37°C as a function of time as 
determined by means of the APTT assay (n=4-+S.D.). 
the APTT assay did not significantly differ from 
those of the factor Xa inactivation assay (see Table 
1). Also the two different oluidine blue assays did 
not significantly differ. However the biological as- 
says yielded much lower values for the amount of 
released heparin than the toluidine blue assays (P< 
0.001). After 8 weeks of incubation of Cuprophan 
heparinized at a weight ratio heparin/CDI of 30 in 
PBS at 37°C, the amount of released heparin as 
determined by means of the APTT was 6.46_+0.81 
U/cm 2. Assuming that the released heparin has the 
same activity as that of the starting material, the 
amount of released heparin equals to 36.5_+4.6 txg/ 
cm 2. The amount of released heparin as determined 
by measuring the amount of immobilized heparin 
before and after incubation by means of the toluidine 
blue membrane assay was 46.8_+ 1.7 txg/cm 2. Appar- 
ently, the relative difference between the amount of 
released heparin as determined by means of the 
APTT and toluidine blue assay decreases with 
increasing incubation times. 
Furthermore, the effects of various sterilization 
methods on the release of heparin were investigated. 
The data were analysed by means of ANOVA 
analysis of variance and considered as significantly 
different when P<0.05. It appeared that sterilization 
of hepaidnized Cuprophan by means of steam, EtO 
exposure, or gamma irradiation did not significantly 
affect the amount of released heparin during 1 week 
of incubation in PBS at 37°C as measured by means 
of the APTT assay (P<0.001; see Table 2). 
3.5. Effect of storage 
The effect of storage on the release properties of 
heparin from heparinized Cuprophan was investi- 
gated. Cuprophan heparinized at a weight ratio of 
heparin/CDI of 30 was exposed to air at ambient 
temperatures for various periods of time up to 6 
months. Thereafter, the membranes were incubated 
Table 1 
Release of heparin from Cuprophan heparinized at different heparin/CDI ratios expressed in wt% (-+S.D.) of the initial amount of 
immobilized heparin after 1 week of incubation in PBS at 37°C as determined by four different methods 
Method of analysis Heparin/CDI=5 a Heparin/CDI = 10" Heparin/CDI=30 a 
APTT b,c 7.3_+0.6 13.3+_0.9 23.2-  + 1.2 
Factor Xa inactivation b'° 7.2-+0.3 13.3-+3.1 25.4-+3.2 
Toluidine blue membrane d 14.8-+2.3 28.2-+5.2 46.3_+2.6 
Toluidine blue solution d'e 13.6_+2.2 27.1 _+2.7 39.5-+5.0 
"Weight ratio applied during heparinization. 
bn=4. 
CThe assays yield the release of heparin in U. The release of heparin expressed in ~g was calculated assuming that the activity of heparin in 
the release medium was the same as that of the starting material (177 U/mg). The amount of immobilized heparin before incubation was 
determined by means of the toluidine blue membrane assay (n=3). The results of both assays were used to calculate the release of heparin 
expressed in wt% of the initially amount of immobilized heparin. 
dn=3. 
°The assay yields the release of heparin in txg. The amount of immobilized heparin before incubation was determined by means of the 
toluidine blue membrane assay (n=3). The results of both assays were used to calculate the release of heparin expressed in wt% of the initial 
amount of immobilized heparin. 
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Table 2 
Release of heparin from non-sterilized and sterilized heparinized Cuprophan after 1 week of incubation in PBS at 37°C expressed in wt% 
(_+S.D.) of the initial amount of immobilized heparin a
Sterilization method Heparin/CDI=5 h Heparin/CDI= 10 b Heparin/CDI=30 b 
Non-sterilized 7.3 _+0.6 13.3 ±0.9 23.2_+ 1.2 
Steam 6.5±0.2 14.7_+1.1 26.5-+2.1 
EtO exposure 5.6±0.4 12.4_+0.8 25.3_+2.2 
Gamma-irradiation 6.1 -+ 0.4 12.3 _+ 0.6 21.9 _+ 1.1 
"The amount of heparin in the release medium was determined by means of the APTT assay (n =4). The assay yields the release of heparin 
in U. The release of heparin expressed in ~xg was calculated assuming that the activity of heparin in the release medium was the same as that 
of the starting material (177 U/mg). The amount of immobilized heparin before incubation was determined by means of the toluidine blue 
membrane assay (n=3). The results of both assays were used to calculate the release of heparin expressed in wt%. 
bWeight ratio applied during heparinization. 
in PBS at 37°C for 1 week. The release of  heparin 
was determined by measuring the amount of  im- 
mobi l ized heparin before and after incubation by 
means of  the toluidine blue membrane assay. The 
results (see Table 3) show that exposure of  heparin- 
ized Cuprophan to air at ambient temperatures up to 
six months did not significantly affect the amount of  
immobi l ized heparin (Student's t: P>0.05) .  Al-  
though the results of  the release measurements were 
somewhat scattered, the release as a function of  
storage t ime showed no clear increase or decrease. 
3.6. Effects of  various treatments on the 
complexation of  heparin with toluidine blue and 
the anticoagulant activity of heparin 
It was investigated whether treatment of  heparin 
with CDI  affects the properties of heparin. In control 
experiments also the effects of  the exchange of 
sodium ions by triton B and subsequent exchange of 
triton B by sodium ions and the dissolution of  
heparin in formamide and PBS were investigated. 
Therefore, the effect of  these treatments on the 
anticoagulant activity (APTT-assay) and the capacity 
of  heparin to complex with toluidine blue (toluidine 
blue solution assay) was determined. As shown in 
Table 4 these treatments had moderate ffects on the 
anticoagulant activity and no significant effects 
(Student's t: P>0.05)  on the capacity of  heparin to 
complex with toluidine blue. 
4. Discussion 
The aim of this study was to evaluate a new 
design for a coating which releases heparin at a 
constant rate for prolonged periods of  t ime and of 
which the release rate can be adjusted. It was 
hypothesized that a coating consisting of  a porous 
structure onto which heparin is immobi l ized via 
hydrolysable bonds should meet these requirements. 
To evaluate this hypothesis, Cuprophan was used as 
Table 3 
Effect of storage time on the amount 
heparin/CDI of 30 (n=3, ±S.D.) 
of immobilized heparin and the release properties of Cupropban heparinized at a weight ratio 
Storage time(months) Amount of immobilized heparin (p~g/cmZ)" 
Before incubation After incubation b 
Release of heparin(%) 
0 63.2_+3.1 - -  - -  
1 65.2_+0.1 37.5 ± 1.0 42.5_+ 1.3 
2.5 63.6_ + 1.0 40.3- + 1.7 36.6-+2.1 
4 63.3-+2.5 34.0_+0.3 46.2-+2.3 
5 65.9_+2.5 39.9_+0.3 39.4±3.7 
6 65.2_+2.9 41.3_+2.2 36.6_+6.3 
aDetermined by means of the toluidine blue membrane assay. 
bMembranes were incubated in PBS/NaN 3 at 37°C for 1 week. 
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Table 4 
Effects of various treatments onthe complexation f heparin with toluidine blue and the anticoagulant activity of heparin 
Treatment Toluidine blue solution (n =3, _+S.D.) a APTT (n =4, -+ S.D.) b 
CDI(30/I) ~ 96.4_+2.2 83.4+_3.3 g 
CDI(5 / 1 )c 97.2 +_ 1.1 92.2+4.5 
Triton B-Hep/form d 96.3_+0.9 88.7+_3.0 g 
Triton B-Hep/NaC1 e 100.5_+2.1 95.2_+5.4 
Na-Hep/PBS f 103.1 _+6.5 102.8_+4.8 
~Degree of complexation f tolnidine blue with treated heparin relative to untreated heparin in %. 
bAnticoagulant activity determined by means of the APTT assay of treated heparin relative to untreated heparin in %. 
°Triton B-heparin dissolved in formamide was treated with CDI (weight ratios heparin/CDI of 5 and 30). Subsequently reated heparin was 
successively precipitated in and thoroughly washed with acetone, dissolved in aqueous 4 M NaC1 (3 days), dialysed against water (6 days), 
and lyophilized. 
aTriton B-heparin was successively dissolved in formamide, precipitated in and thoroughly washed with acetone, dissolved in aqueous 4 M 
NaC1 (3 days), dialysed against water (6 days), and lyophilized. 
~Triton B-heparin was successively dissolved in aqueous 4 M NaC1 (3 days), dialysed against water (6 days), and lyophilized. 
fNa-heparin was dissolved in PBS/NaN 3 and stored for 1 week at 37°C. The solution was subsequently diaiysed against water (2 days) and 
then lyophilized. 
gSignificantly different from Na-Hep/PBS (Student's t: P<0.05). 
a model substrate and CDI was used as a coupling 
agent to immobil ize heparin. 
The results of the present study confirm the 
hypothesis. Cuprophan heparinized by means of the 
CDI-activation procedure forms an ideal system for 
the controlled release of heparin. The release profiles 
can be adjusted very easily by changing the heparin/ 
CDI ratio applied during heparinization. Further- 
more, the heparin release rate of Cuprophan heparin- 
ized at weight ratios heparin/CDI of 5 and 10 
remained constant for at least 1 week of incubation 
in PBS at 37°C. When the rate of heparin release is 
relatively high as found in the case of Cuprophan 
heparinized at a weight ratio heparin/CDI of 30, a 
constant heparin release rate was limited to 3 days of 
incubation after which the release rate gradually 
decreased. 
The effect of the heparin/CDI ratio on the release 
properties clearly indicates that the release of heparin 
is due to the cleavage of covalent bonds. The more 
CDI is used, the more covalent bonds between 
heparin and Cuprophan will be formed. Therefore, 
the release rate will decrease when the heparin/CDI 
ratio is decreased. FTIR-spectroscopy also confirmed 
that the release of heparin is due to the cleavage of 
covalent bonds. The carbonyl groups of the covalent 
bonds between heparin and Cuprophan give rise to 
an absorption peak around 1740 cm -1. After 1 week 
of incubation, the surface area of this peak was much 
smaller (data not shown). 
CO2-release experiments and experiments with 
model compounds howed that activation of heparin 
with CDI yields more than twice as many activated 
carboxylic acid groups than activated hydroxyl 
groups and that activated carboxylic acid groups 
react much faster with hydroxyl groups of Cup- 
rophan than activated hydroxyl groups. Furthermore, 
in 13C-NMR spectra of products of the reaction 
between CDI-activated heparin with model com- 
pounds only ester bonds and no carbonate bonds 
could be identified. The results of the CO 2 release 
experiments and the model reactions strongly indi- 
cate that heparinization of Cuprophan by means of 
the CDI activation procedure yielded (nearly) only 
ester bonds and no (or hardly any) carbonate bonds. 
These findings are in agreement with the results of 
Staab [31] who studied the coupling of small organic 
compounds using CDI. He also found that ester 
bonds are more easily formed than carbonate bonds. 
It is well-known that ester bonds are susceptible to 
hydrolysis. Therefore, it is concluded that the release 
of heparin is due to the hydrolysis of ester bonds 
between heparin and Cuprophan. The rate of hy- 
drolysis of these bonds was relatively high. The 
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model compound, benzoic acid, was also immobil- 
ized onto Cuprophan via ester bonds. Incubation of 
these membranes in PBS resulted in a very slow 
hydrolysis of the esters bonds. The difference may 
be caused by the fact that heparin is negatively 
charged in PBS. These negative charges may have a 
catalytic effect on the hydrolysis of ester bonds. 
Exposure of heparinized Cuprophan to air at 
ambient temperature up to six months did neither 
significantly affect the amount of immobilized 
heparin nor the release properties. Apparently, the 
covalent bonds between heparin and Cuprophan are 
stable towards moisture in the air at ambient em- 
perature for a long period of time. It can be expected 
that due to the hydrophilicity of heparinized Cup- 
rophan water will absorb from the air. Absorption of 
water may lead to hydrolysis of the ester bonds 
between heparin and Cuprophan. As found, exposure 
to air at ambient temperature did not result in 
significant hydrolysis of covalent linkages between 
heparin and Cuprophan. Possibly not enough water 
had absorbed but also temperature effects may have 
played an important role. The membranes were 
exposed to air at ambient emperature whereas the 
release experiments were carried out at 37°C. It is 
known that the hydrolysis of ester bonds can strongly 
depend on temperature. Preliminary experiments 
indeed showed that the release of heparin from 
heparinized Cuprophan incubated in PBS dramatical- 
ly decreases when the temperature is decreased (data 
not shown). Sterilization of heparinized Cuprophan 
by means of steam, EtO exposure, or gamma irradia- 
tion did not affect the release properties. Apparently, 
also these treatments had no effect on the covalent 
linkages between heparin and Cuprophan. Further- 
more neither significant cleavage of heparin chains 
nor modification of immobilized heparin had 
occurred during sterilization. 
The release of heparin from heparinized Cup- 
rophan after 1 week of incubation in PBS at 37°C 
was investigated by means of the APTT, factor Xa 
inactivation, toluidine blue membrane, and toluidine 
blue solution assays. The APTT and factor Xa 
inactivation assays are based on the anticoagulant 
activity of heparin whereas both toluidine blue 
assays are based on the complexation of toluidine 
blue with the negative charges of heparin. To 
compare the results of the four different assays, the 
release of heparin in wt% of the initial amount of 
immobilized heparin was calculated with the as- 
sumptions that heparin released from the membrane 
had the same anticoagulant activity and complexed 
with toluidine blue in the same ratio as the starting 
material (see Table 1). Because these calculations 
yielded much lower values for the release determined 
by both biological assays than those determined by 
both chemical assays, it is clear that the assumptions 
mentioned above are not valid. It was therefore 
investigated whether the properties of heparin were 
affected uring the immobilization procedure and/or 
incubation in PBS at 37°C. These control experi- 
ments, however, revealed that these treatments had 
no or moderate ffects on the anticoagulant activity 
of heparin or the capacity of heparin to complex with 
toluidine blue (see Table 4). The results of the APTT 
and the toluidine blue membrane assays were in 
better agreement when heparinized Cuprophan was 
incubated in PBS at 37°C for 8 weeks instead of 1 
week. These results indicate that the differences 
between the results of biological and chemical assays 
can be ascribed by the following mechanism. 
Heparin is a polydisperse polysaccharide containing 
fractions of various anticoagulant activities and 
molecular weights. Because the anticoagulant activi- 
ty of heparin increases with increasing molecular 
weight [32-34], the number of covalent bonds 
between heparin and Cuprophan will increase with 
increasing anticoagulant activity. The less covalent 
bonds between a heparin molecule and Cuprophan 
exists, the easier the heparin molecule will be 
released. Therefore, the anticoagulant activity of 
heparin released from the membrane will increase 
with the incubation time until all heparin is released. 
At that time, the average activity of all heparin 
released will be the same as that of the starting 
material. The gross chemical structures of heparin 
fractions of different anticoagulant activities are very 
similar [33,34]. Therefore, the complexation charac- 
teristics of heparin with toluidine blue will be 
independent of the anticoagulant activity. Conse- 
quently, the capacity of heparin released from the 
membrane to complex with toluidine blue will not 
change with the incubation time and will be the same 
as that of the starting material. Therefore the differ- 
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ences between the calculated values for the release of 
heparin in wt% using the results of the biological and 
chemical assays will be large at short incubation 
times but will decrease with increasing incubation 
times. 
Heparinization of Cuprophan by means of the 
CDI-activation procedure yielded membranes with 
60-85 txg of immobilized heparin per cm 2 mem- 
brane surface. These amounts of immobilized 
heparin are much higher than when only a monolayer 
of heparin at the surface of the membrane would 
have formed. In that case a density of 0.1-2.0 p~g of 
immobilized heparin per cm 2 is expected [35]. 
Cuprophan has a porous structure with pores of 25 
in diameter when swollen in water [36]. Colton et al. 
[37] and Klein et al. [38] showed that Cuprophan is 
permeable for heparin. Therefore, it can be assumed 
that heparin is also immobilized in the pores of the 
membrane. Given the amount of heparin released 
from the membrane, it is clear that heparin immobil- 
ized in the pores also contributes to the release. The 
effects of the diffusion characteristics of heparin in 
the porous matrix on the release profiles, however, 
remain unclear. A high amount of immobilized 
heparin is necessary to allow for a release of 
substantial amounts of heparin during prolonged 
periods of time. Those amounts of immobilized 
heparin can never be reached when the immobiliza- 
tion of heparin is restricted to the surface of the 
membrane. The results of our study show that 
application of porous structures can overcome this 
problem because the pores provide a very large 
surface area for the immobilization of high amounts 
of heparin. 
As mentioned above, the relatively high heparin 
release rate, as observed with Cuprophan heparinized 
at a weight ratio heparin/CDI of 30, remained 
constant for 3 days after which it decreased. Most 
likely, this decrease was due to the substantial 
depletion of the amount of immobilized heparin. 
Although the initial release rate of Cuprophan 
heparinized at a weight ratio heparin/CDI of 30 is 
relatively high, it may not be sufficient to assure 
thromboresistance. Furthermore, a constant release 
rate of 3 days may be too short. It can be expected 
that if more heparin is immobilized, the release rate 
will be higher and will be constant for a prolonged 
period of time. An increased amount of immobilized 
heparin can for example be achieved by the applica- 
tion of membranes with increased thickness and/or 
porosity. Furthermore, the release rate can be in- 
creased by increasing the heparin/CDI ratio applied 
during heparinization. 
Application of the concept for a heparin release 
system as described in this study will not be re- 
stricted to cellulosic membranes as substrates. Also 
other porous substrates might be applicable pro- 
viding that these materials possess hydroxyl groups 
which are necessary to immobilize heparin via 
hydrolysable bonds by means of the CDI-activation 
procedure. Because not only the heparin/CDI ratio 
but also the substrate characteristics an be varied, 
controlled release systems with a very broad range of 
heparin release rates which remain constant for 
prolonged periods of time can be established. These 
controlled release systems used as coatings may 
successfully prevent hrombus formation at the sur- 
face of blood contacting devices for various applica- 
tions. 
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